» Articles » PMID: 33481105

Supratentorial Ependymoma in Childhood: More Than Just RELA or YAP

Abstract

Two distinct genetically defined entities of ependymoma arising in the supratentorial compartment are characterized by the presence of either a C11orf95-RELA or a YAP-MAMLD1 fusion, respectively. There is growing evidence that supratentorial ependymomas without these genetic features exist. In this study, we report on 18 pediatric non-RELA/non-YAP supratentorial ependymomas that were systematically characterized by means of their histology, immunophenotype, genetics, and epigenomics. Comprehensive molecular analyses included high-resolution copy number analysis, methylation profiling, analysis of fusion transcripts by Nanostring technology, and RNA sequencing. Based upon histological and immunohistochemical features two main patterns were identified-RELA-like (n = 9) and tanycytic ependymomas (n = 6). In the RELA-like group histologically assigned to WHO grade III and resembling RELA-fused ependymomas, tumors lacked nuclear expression of p65-RelA as a surrogate marker for a pathological activation of the NF-κB pathway. Three tumors showed alternative C11orf95 fusions to MAML2 or NCOA1. A methylation-based brain tumor classifier assigned two RELA-like tumors to the methylation class "EP, RELA-fusion"; the others demonstrated no significant similarity score. Of the tanycytic group, 5/6 tumors were assigned a WHO grade II. No gene fusions were detected. Methylation profiling did not show any association with an established methylation class. We additionally identified two astroblastoma-like tumors that both presented with chromothripsis of chromosome 22 but lacked MN1 breaks according to FISH analysis. They revealed novel fusion events involving genes in chromosome 22. One further tumor with polyploid cytogenetics was interpreted as PFB ependymoma by the brain tumor methylation classifier but had no relation to the posterior fossa. Clinical follow-up was available for 16/18 patients. Patients with tanycytic and astroblastoma-like tumors had no relapse, while 2 patients with RELA-like ependymomas died. Our data indicate that in addition to ependymomas discovered so far, at least two more supratentorial ependymoma types (RELA-like and tanycytic) exist.

Citing Articles

Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.

Okonechnikov K, Ghasemi D, Schrimpf D, Tonn S, Mynarek M, Koster J Acta Neuropathol Commun. 2025; 13(1):4.

PMID: 39762990 PMC: 11706152. DOI: 10.1186/s40478-024-01921-w.


Advances in molecular prognostication and treatments in ependymoma.

Bakes E, Cheng R, Manucat-Tan N, Ramaswamy V, Hansford J J Neurooncol. 2025; .

PMID: 39757304 DOI: 10.1007/s11060-024-04923-9.


Sex Differences in Ependymoma Methylation by Methylation-Defined Subgroup.

Mestnik S, Sorajja N, Lu Z, Mills L, Williams L J Cell Mol Med. 2024; 28(24):e70286.

PMID: 39679838 PMC: 11647990. DOI: 10.1111/jcmm.70286.


Metabolism: an important player in glioma survival and development.

Wang N, Yuan Y, Hu T, Xu H, Piao H Discov Oncol. 2024; 15(1):577.

PMID: 39436434 PMC: 11496451. DOI: 10.1007/s12672-024-01402-5.


Concurrent ependymal and ganglionic differentiation in a subset of supratentorial neuroepithelial tumors with EWSR1-PLAGL1 rearrangement.

Lee J, Koo S, Furtado L, Breuer A, Eldomery M, Bag A Acta Neuropathol Commun. 2024; 12(1):143.

PMID: 39228008 PMC: 11370057. DOI: 10.1186/s40478-024-01809-9.


References
1.
Pietsch T, Wohlers I, Goschzik T, Dreschmann V, Denkhaus D, Dorner E . Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. Acta Neuropathol. 2014; 127(4):609-11. DOI: 10.1007/s00401-014-1264-4. View

2.
Sturm D, Orr B, Toprak U, Hovestadt V, Jones D, Capper D . New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016; 164(5):1060-1072. PMC: 5139621. DOI: 10.1016/j.cell.2016.01.015. View

3.
Takeshita A, Yen P, Misiti S, Cardona G, Liu Y, Chin W . Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology. 1996; 137(8):3594-7. DOI: 10.1210/endo.137.8.8754792. View

4.
Junger S, Mynarek M, Wohlers I, Dorner E, Zur Muhlen A, Velez-Char N . Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathol Commun. 2019; 7(1):181. PMC: 6857225. DOI: 10.1186/s40478-019-0820-5. View

5.
Pajtler K, Witt H, Sill M, Jones D, Hovestadt V, Kratochwil F . Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015; 27(5):728-43. PMC: 4712639. DOI: 10.1016/j.ccell.2015.04.002. View